Ancillary tests for hepatobiliary neoplasms: what we know and what we need to know

被引:2
|
作者
Zhang, Sarah L. [1 ]
Wang, Hanlin L. [2 ]
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA
[2] UCLA, Dept Pathol & Lab Med, David Geffen Sch Med, 10833 Le Conte Ave, Los Angeles, CA 90095 USA
关键词
Hepatocellular carci-noma; Hepatocellular adenoma; Bile duct; Cholangiocarcinoma; Metastatic carcinoma; Biomarker; IN-SITU-HYBRIDIZATION; LINDAU GENE-PRODUCT; C-REACTIVE PROTEIN; DIFFERENTIATING HEPATOCELLULAR-CARCINOMA; CELL NUCLEAR ANTIGEN; INTRAHEPATIC CHOLANGIOCARCINOMA; GLUTAMINE-SYNTHETASE; DIAGNOSTIC UTILITY; BILIARY-TRACT; IMMUNOHISTOCHEMICAL MARKERS;
D O I
10.1016/j.humpath.2023.02.001
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Ancillary tests are commonly used in the surgical pathology setting for diagnosing challenging neoplastic diseases of the liver and biliary tract, while histology and clinical correlation remain to be critically important. With continuous discoveries, more and more useful ancillary tests have become available, which can help distinguish between malignant and benign hepatocellular neoplasms, malignant and benign biliary tract entities, and intrahepatic and metastatic carcinomas. This review will focus on existing and emerging biomarkers (such as glutamine synthetase, organic anion transporting polypeptide 1B3, insulin-like growth factor-II mRNA binding protein-3, S100P, SMAD4, enhancer of zeste homolog 2, albumin, hepatocyte nuclear factor-1b, etc.) that can be used for the diagnosis, classification and prognostication of hepatobiliary neoplasms. (c) 2023 The Author(s). Published by Elsevier Inc.
引用
收藏
页码:183 / 200
页数:18
相关论文
共 50 条
  • [41] MRI contrast media: What clinicians need to know
    Das, Chandan J.
    Mahalingam, Sowmya
    Debnath, Jyotindu
    Dhawan, Sanjay
    NATIONAL MEDICAL JOURNAL OF INDIA, 2010, 23 (05) : 292 - 296
  • [42] CSF metabolomics alterations after aneurysmal subarachnoid hemorrhage: what do we know?
    Ho, Wing Mann
    Schmidt, Franziska A.
    Thome, Claudius
    Petr, Ondra
    ACTA NEUROLOGICA BELGICA, 2023, 123 (06) : 2111 - 2114
  • [43] CSF metabolomics alterations after aneurysmal subarachnoid hemorrhage: what do we know?
    Wing Mann Ho
    Franziska A. Schmidt
    Claudius Thomé
    Ondra Petr
    Acta Neurologica Belgica, 2023, 123 : 2111 - 2114
  • [44] Identifying High-Risk NASH Patients: What We Know so Far
    Schulz, Marten
    Tacke, Frank
    HEPATIC MEDICINE-EVIDENCE AND RESEARCH, 2020, 12 : 125 - 137
  • [45] Lung cancer biomarkers - Where we are and what we need
    Stieber, Petra
    Holdenrieder, Stefan
    CANCER BIOMARKERS, 2010, 6 (3-4) : 221 - 224
  • [46] Infiltrative Hepatocellular Carcinoma: What Radiologists Need to Know
    Reynolds, Arich R.
    Furlan, Alessandro
    Fetzer, David T.
    Sasatomi, Eizaburo
    Borhani, Amir A.
    Heller, Matthew T.
    Tublin, Mitchell E.
    RADIOGRAPHICS, 2015, 35 (02) : 371 - 386
  • [47] Early markers of gestational diabetes mellitus: what we know and which way forward?
    Omazic, Jelena
    Viljetic, Barbara
    Ivic, Vedrana
    Kadivnik, Mirta
    Zibar, Lada
    Muller, Andrijana
    Wagner, Jasenka
    BIOCHEMIA MEDICA, 2021, 31 (03)
  • [48] Folate Metabolism in Hepatocellular Carcinoma. What Do We Know So Far?
    Quevedo-Ocampo, Jaqueline
    Escobedo-Calvario, Alejandro
    Souza-Arroyo, Veronica
    Miranda-Labra, Roxana U.
    Bucio-Ortiz, Leticia
    Gutierrez-Ruiz, Maria C.
    Chavez-Rodriguez, Lisette
    Gomez-Quiroz, Luis E.
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2022, 21
  • [49] PAX8 as a Potential Target for Ovarian Cancer: What We Know so Far
    Di Palma, Tina
    Zannini, Mariastella
    ONCOTARGETS AND THERAPY, 2022, 15 : 1273 - 1280
  • [50] Pulmonary Remodeling in Equine Asthma: What Do We Know about Mediators of Inflammation in the Horse?
    Barton, Ann Kristin
    Gehlen, Heidrun
    MEDIATORS OF INFLAMMATION, 2016, 2016